Home Healthcare Pharmaceuticals Apixaban Market

Apixaban Market Size, Share & Trends Analysis Report By Dosage Strength (2.5 mg, 5 mg), By Indication (Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Post-Operative Venous Thromboembolism Prophylaxis), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: October 13, 2026 | Author: Straits Research Team | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Apixaban Market, By Dosage Strength 2025-2034 (USD MILLION/ Units)
    1. 2.5 mg
    2. 5 mg
  2. Apixaban Market, By Indication 2025-2034 (USD MILLION/ Units)
    1. Atrial Fibrillation
    2. Deep Vein Thrombosis
    3. Pulmonary Embolism
    4. Post-Operative Venous Thromboembolism Prophylaxis
  3. Apixaban Market, By Distribution Channel 2025-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. Online Pharmacies
  4. Regional Apixaban Market
    1. North America
      1. North America Apixaban Market By Dosage Strength 2025-2034 (USD MILLION/ Units)
        1. 2.5 mg
        2. 5 mg
      2. North America Apixaban Market By Indication 2025-2034 (USD MILLION/ Units)
        1. Atrial Fibrillation
        2. Deep Vein Thrombosis
        3. Pulmonary Embolism
        4. Post-Operative Venous Thromboembolism Prophylaxis
      3. North America Apixaban Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. U.S.
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      5. Canada
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
    2. Europe
      1. Europe Apixaban Market By Dosage Strength 2025-2034 (USD MILLION/ Units)
        1. 2.5 mg
        2. 5 mg
      2. Europe Apixaban Market By Indication 2025-2034 (USD MILLION/ Units)
        1. Atrial Fibrillation
        2. Deep Vein Thrombosis
        3. Pulmonary Embolism
        4. Post-Operative Venous Thromboembolism Prophylaxis
      3. Europe Apixaban Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. U.K.
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      5. Germany
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      6. France
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      7. Spain
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      8. Italy
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      9. Russia
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      10. Nordic
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      11. Benelux
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      12. Rest of Europe
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
    3. APAC
      1. APAC Apixaban Market By Dosage Strength 2025-2034 (USD MILLION/ Units)
        1. 2.5 mg
        2. 5 mg
      2. APAC Apixaban Market By Indication 2025-2034 (USD MILLION/ Units)
        1. Atrial Fibrillation
        2. Deep Vein Thrombosis
        3. Pulmonary Embolism
        4. Post-Operative Venous Thromboembolism Prophylaxis
      3. APAC Apixaban Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. China
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      5. Korea
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      6. Japan
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      7. India
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      8. Australia
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      9. Taiwan
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      10. South East Asia
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      11. Rest of Asia-Pacific
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
    4. Middle East and Africa
      1. Middle East and Africa Apixaban Market By Dosage Strength 2025-2034 (USD MILLION/ Units)
        1. 2.5 mg
        2. 5 mg
      2. Middle East and Africa Apixaban Market By Indication 2025-2034 (USD MILLION/ Units)
        1. Atrial Fibrillation
        2. Deep Vein Thrombosis
        3. Pulmonary Embolism
        4. Post-Operative Venous Thromboembolism Prophylaxis
      3. Middle East and Africa Apixaban Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. UAE
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      5. Turkey
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      6. Saudi Arabia
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      7. South Africa
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      8. Egypt
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      9. Nigeria
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      10. Rest of MEA
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
    5. LATAM
      1. LATAM Apixaban Market By Dosage Strength 2025-2034 (USD MILLION/ Units)
        1. 2.5 mg
        2. 5 mg
      2. LATAM Apixaban Market By Indication 2025-2034 (USD MILLION/ Units)
        1. Atrial Fibrillation
        2. Deep Vein Thrombosis
        3. Pulmonary Embolism
        4. Post-Operative Venous Thromboembolism Prophylaxis
      3. LATAM Apixaban Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. Brazil
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      5. Mexico
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      6. Argentina
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      7. Chile
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      8. Colombia
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
      9. Rest of LATAM
        1. 2.5 mg
        2. 5 mg
        3. Atrial Fibrillation
        4. Deep Vein Thrombosis
        5. Pulmonary Embolism
        6. Post-Operative Venous Thromboembolism Prophylaxis
        7. Hospital Pharmacies
        8. Drug Stores & Retail Pharmacies
        9. Online Pharmacies
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.